Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis

Journal of Dermatological Treatment

Volumn 26, Issue 1, 2015, Pages 7-15

  Puig, Luis ^a   Strohal, Robert ^b   Husni, M Elaine ^c   Tsai, Tsen Fang ^d   Noppakun, Nopadon ^e   Szumski, Annette ^f   Yang, Shiyi ^f   Robertson, Deborah ^f   Boggs, Robert ^f   Koenig, Andrew S ^f  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Academic Teaching Hospital Feldkirch   (Austria)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^f PFIZER INC   (United States)

Author keywords

Cardiovascular disease risk; Disease characteristics; Efficacy; Etanercept

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ELEVATED BLOOD PRESSURE; FEMALE; HUMAN; MALE; MEDICAL HISTORY; METABOLIC SYNDROME X; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; ARTHRITIS, PSORIATIC; PSORIASIS;

ADULT; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84924322803     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.860209     Document Type: Article

References (54)

1. National Psoriasis Foundation. About psoriasis: statistics. Available from http://www.psoriasis.org/netcommunity/learn-statistics. Accessed February 28, 2013.
2. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3-11.
3. Gladman DD. Psoriatic arthritis from Wright's era until today. J Rheumatol Suppl. 2009;83:4-8.
4. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145:700-3.
5. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-9.
6. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J. 2010;31:1000-6.
7. Han C, Lofland JH, Zhao N, et al. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10:843-50.
8. Husted JA, Tom BD, Farewell VT, et al. Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2012; 64:758-65.
9. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151-8.
10. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
11. Taylor WJ, Mease PJ, Adebajo A, et al. Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol. 2010;37:1885-91.
12. Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012;51: 275-83.
13. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14-7.
14. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356:385-90.
15. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340: c147-55.
16. Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2012;24: 169-78.
17. Puig L, Strohal R, Fuiman J, et al. High prevalence of the metabolic syndrome in patients with chronic plaque psoriasis: Impact of etanercept therapy on cardiometabolic biomarkers. J Dermatol Treat. 2013;24:169-78.
18. Thaci D, Galimberti R, Amaya-Guerra M, et al. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol. 2013. Jul 15. doi: 10.1111/jdv.12207. [Epub ahead of print].
19. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
20. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care. 2010;33:S11-61.
21. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-97.
22. Framingham Heart Study. Hard coronary heart disease (10-year risk). Available from http://www.framinghamheartstudy.org/risk/ hrdcoronary.html. Accessed February 28, 2013.
23. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: 1837-47.
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-421.
25. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-9.
26. Kind P, Hardman G, Macron S. UK population norms for EQ-5D (Measurement and Valuation of Health National Survey). Available from http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf. Accessed February 28, 2013.
27. Sobocki P, Ekman M, Agren H, et al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health. 2007;10:153-60.
28. Lillegraven S, Kvien TK. Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:827-40.
29. van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes. 2006;4:20-9.
30. Xie J, Wu EQ, Zheng ZJ, et al. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke. 2006;37:2567-72.
31. Ståhl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3:56-64.
32. Glasziou P, Alexander J, Beller E, et al. Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007;5:21-32.
33. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16: 199-208.
34. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lipincott- Raven, 1996. p. 191-201.
35. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-108.
36. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79-86.
37. Cella D, Eton DT, Lai JS, et al. Combining anchor and distributionbased methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24:547-61.
38. Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528-38.
39. Hays RD, Martin SA, Sesti AM, et al. Psychometric properties of the medical outcomes study sleep measure. Sleep Med. 2005;6:41-4.
40. Rejas J, Ribera MV, Ruiz M, et al. Psychometric properties of the MOS (medical outcomes study) sleep scale in patients with neuropathic pain. Eur J Pain. 2007;11:329-40.
41. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
42. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130: 1785-96.
43. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol. 2010;130:919-22.
44. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145:379-82.
45. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416-22.
46. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2012;72:211-6.
47. Raychaudhuri SP. Comorbidities of psoriatic arthritis - metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:437-40.
48. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
49. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51:552-6.
50. Patel RV, Shelling ML, Prodanovich S, et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011;26:1036-49.
51. Mente A, Yusuf S, Islam S, et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol. 2010;55:2390-8.
52. Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222-32.
53. Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244-50.
54. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic antiinflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197-204.